A Unique Roadblock for Pfizer’s Osteoarthritis Drug
We’ve heard of drugs underperforming in clinical trials, but is it possible for a drug to over-perform?
808
Researchers, Healthcare Companies Seek to Give COPD Patients Some Breathing Room
Breathing is one of the most basic human functions, but for an estimated 12 million people in the United States, the simple act of drawing a breath can be difficult and even painful.
No Shortage of Hopefuls in the Multibillion-Dollar Blood Thinner Business
Patients hoping for a new alternative to the blockbuster blood thinner Plavix will have to wait a bit longer for a verdict on a promising candidate.
FDA Hopes to Keep Pharma Honest With “Bad Ad” Program
Last week, the FDA unveiled its “Bad Ad” program to encourage physicians to report questionable pharmaceutical sales pitches.
Immune-Based Treatments for Brain Cancer Post Impressive Early-Stage Results
Approximately 19,000 individuals in the US are diagnosed with primary brain cancers each year.
FDA to Collaborate with Pharma Companies on New TB Initiative
A number of pharmaceutical companies will collaborate with FDA scientists to test new TB combination therapies and identify promising candidates.
Cancer Vaccines: Investing Opportunities Beyond Dendreon
Despite the setbacks and pitfalls experienced by early-stage pioneers in the cancer immunotherapy / therapeutic cancer vaccine space, recent advancements and study results are encouraging.
NicOx Reports Positive Data for Cholesterol Drug
NicOx announced that NCX 6560, its drug candidate for high cholesterol, met its primary and secondary endpoints in a Phase Ib man-in study.
Ligand to Buy Struggling Metabasis
Ligand Pharmaceuticals has agreed to buy the struggling Metabasis Therapeutics for $3.2 million in cash.
Melanoma Drug Called a “Breakthrough” After Study
Scientists are calling Plexxikon’s experimental skin cancer drug a “breakthrough” after it successfully shrank tumors in clinical trial patients.